Forty Seven IPO $115 million and released the latest data
June 05, 2018 Source: Sina Pharmaceutical
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];In recent years, research on tumors has become an unprecedented hot spot. Thanks to the efficient transformation of results, many researchers have stepped out of the school to set up a separate technology company to get it into the clinic as soon as possible. Irv Weissman from Stanford University recently established Forty Seven and announced the successful completion of an initial public offering of $115 million.
Forty Seven, an emerging biopharmaceutical company founded in early 2015, has achieved many successes in its founding in just one year. In February 2016, they received $75 million in Series A funding and two Phase I clinical trials are underway. The company has licensed more than 100 patents from Stanford University, including Hu5F9-G4, a key humanized anti-CD47 monoclonal antibody. Irv Weissman et al. have long been engaged in the study of CD47 molecules, and two anti-CD47 molecular antibodies Hu5F9-G4 have been studied.
The company published conceptual data on major drugs at the annual meeting of the American Society of Clinical Oncology (ASCO). This included preliminary data on 22 patients taking 5F9. The early data from this group were impressive: 15 patients with drug-resistant diffuse large B-cell lymphoma (DLBCL) and 7 patients with follicular lymphoma . The results showed that in the DLBCL test group, the objective response rate was 40%, and the complete response rate was as high as one-third. In follicular lymphoma, the objective response rate was 71%, and the complete response rate reached 43%.
It is still too early to set the median rate based on the duration of the response, but the researchers said that during the close follow-up, only one patient developed tumor progression after 6 months. Forty Seven plans to combine the study as a monotherapy with PD-1/PD-L1 and CTLA-4 checkpoint inhibitors, starting with Genentech Tecentriq.
Also known as integrin-associated protein, CD47 is a member of the immunoglobulin superfamily and is widely expressed on the surface of cells. It interacts with signal-regulating protein alpha, thrombospondin and integrin to mediate apoptosis, proliferation, and immunity. Wait for a series of reactions. If macrophages are to exert phagocytosis, two signals need to be stimulated at the same time: one is to activate the "eat me" signal on the surface of the cancer cell, and the other is to inactivate the signal "don't eat me" on the surface of the cancer cell. Experiments have shown that CD47 is a kind of "don't eat me" signal, which inhibits the phagocytosis of macrophages by binding to SIRP-α on the surface of macrophages. CD47 is widely expressed on the surface of various cancer cells, so it can be used to treat various types of cancer with CD47 as a target.
The normal cells in the human body lack the "eat me" signal, and blocking CD47 alone does not induce the phagocytic effect of macrophages on normal cells, so the blocking of CD47 is effective and safe. 5F9 can cause the inactivation of CD47 signal, thereby stimulating the phagocytosis of cancer cells by the patient's own macrophages, and the antigen presenting effect of macrophages on cancer cell antigens also stimulates T cells to attack cancer cells.
"In many types of immunotherapy, target cells are killed and their cellular contents are spilled, leading to an uncontrolled immune response," Professor Samuel Cheshier said. "Anti-CD47 antibodies may produce fewer such side effects. Of course, this needs to be further confirmed."
So far, the company has raised about $149 million and spent about $84 million. (Sina Pharmaceutical Compilation / Fan Dongdong)
Article reference source: Stanford spinout Forty Seven arrives at ASCO with a snapshot of promising CD47 data — and a $115M IPO in hand
Maxillofacial fixation system -- micro-plate for cranial and maxillofacial fracture fixation, designed for the surgical treatment of maxillofacial trauma fractures, suitable for the forehead, nose, orbit, zygomatic, maxillary region, and pediatric craniofacial bones.
The system is an orthopedic surgical instrument for neurosurgical tools. The maxillofacial fixation system includes micro-plates, straight plates, L-shaped plates, T-shaped plates, Y-shaped plates, double Y-shaped plates, H-shaped plates for cranial and maxillofacial fractures. The product range is complete, covering three-dimensional titanium mesh, self-drilling rotary bone screws, anatomical orbital floor plates, orthodontic nails, etc. However, the facial anatomical structure is special, and the screw plate needs to be placed away from the fracture line and avoid important anatomical structures such as nerves and teeth roots. Therefore, the specifications of the screw plate system are required to be as diverse as possible in order to be used in different bone structures, such as different radian, length, and number of screw holes. The bone plates forcranial and maxillofacial fractures are mainly divided into 1.5mm, 2.0mm and 2.4mm systems.
Titanium (including pure titanium and titanium alloy) is the most common material for hard tissue implants. Its elastic modulus and tensile strength are higher than those of human bone, and it is better than other metal materials such as nickel-titanium alloy and cobalt-chromium alloy in terms of biocompatibility and corrosion resistance. Our maxillofacial plate is made of titanium, and the self-tapping screws are mainly made of titanium alloy.
Jaw fractures include maxillary fractures and mandibular fractures. According to whether the fracture trauma is exposed, it can be divided into open fracture and closed fracture. Trauma is the most common cause of jaw fracture, which usually includes hit, traffic injury, fall injury, firearm injury, and a few iatrogenic injuries. All are caused by external forces acting directly or indirectly on the maxillofacial region. With the popularization of motor vehicles, the proportion of jaw fractures caused by traffic accidents has increased year by year, which has become the main cause of jaw fractures. In addition, neoplastic lesions in the maxillofacial region often lead to pathological jaw fractures.
In summary, maxillofacial fixation system has been widely used in clinical maxillofacial surgery, plastic surgery and ENT, and has a relatively mature market.
Titanium Plate,Rectangular Plate,orthognathic surgery,oral and maxillofacial
Jiangsu Aomed Ortho Medical Technology Co.,Ltd , https://www.aomedortho.com